Singapore's BioLynx To Market Molecular Tool For Malaria Treatment
This article was originally published in PharmAsia News
Executive Summary
Singapore's BioLynx Technologies, a recent spinoff of the National University of Singapore, plans to develop and market tools for assisting malaria research